ArticleInternational journal of nanomedicine2026
Dual-Action Theranostic Nanoparticles Delivering Toll-Like Receptor 2 Inhibitors and Chemotherapy Target Breast Cancer Cells and the Tumor Microenvironment.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Preparation of HLYVSPW peptide-displaying outer membrane vesicles and validation of their in vitro targeting effects on triple-negative breast cancer cells].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Breast cancer remains the leading cause of cancer-related death in women, largely due to therapy resistance driven by both tumor-intrinsic and tumor microenvironment (TME)-mediated mechanisms. Toll-like receptor 2 (TLR2), which is overexpressed in breast tumors, promotes cancer progression and chemoresistance through both cancer-cell intrinsic and immune-mediated signaling, making it a promising therapeutic target. Methods: We developed a targeted therapy combining two types of nanoparticles (NPs) for targeted drug delivery, hybrid poly (lactic-co-glycolic acid) (PLGA)- lipid NPs loaded with the TLR2 inhibitor CU-CPT22 (PLGA-CU) and liposomes encapsulating doxorubicin (LIPO-DOXO). Both NP types were functionalized with cyclic RGD peptides to target α Results: PLGA-CU effectively inhibited TLR2 signaling. Both PLGA-CU and LIPO-DOXO reduced cell viability and induced apoptosis, with stronger effects observed when used in combination. In vivo imaging confirmed the accumulation of NPs in tumors. While monotherapies reduced tumor growth, the combined treatment targeted both cancer cells and TME, leading to reduced angiogenesis and immunosuppression, as well as enhanced anti-tumor activity. Conclusion: NP-mediated delivery of a TLR2 inhibitor and doxorubicin produces synergistic anti-cancer effects in breast cancer models. This approach may help overcome chemoresistance and improve therapeutic outcomes, offering a promising strategy for the treatment of advanced breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.